- Home
- BBIO vs AXSM Comparison
BBIO vs AXSM Comparison
Compare BBIO & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBIO | AXSM |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 12.0B |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BBIO | AXSM |
|---|---|---|
| Price | $69.97 | $241.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 25 | 17 |
| Target Price | $86.33 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 2.7M | 670.5K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $502,076,000.00 | N/A |
| Revenue This Year | $89.45 | $57.24 |
| Revenue Next Year | $73.78 | $55.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 126.26 | N/A |
| 52 Week Low | $41.80 | $96.09 |
| 52 Week High | $84.94 | $260.19 |
Technical Indicators
Market Signals| Indicator | BBIO | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 54.49 |
| Support Level | $62.94 | $148.87 |
| Resistance Level | $71.74 | N/A |
| Average True Range (ATR) | 2.24 | 8.48 |
| MACD | 0.44 | -2.13 |
| Stochastic Oscillator | 84.55 | 40.66 |
Price Performance
Historical ComparisonAbout BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.